Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
2
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 370
- Registration Number
- NCT06633783
- Locations
- 🇨🇳
Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Huizhou Central People's Hospital, Huizhou, Guangdong, China
🇨🇳Luoyang Third People's Hospital, Luoyang, Henan, China
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 476
- Registration Number
- NCT05816057
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳NanFang Hospital, Guangzhou, Guangdong, China
🇨🇳CANGZHOU People's Hospital, Cangzhou, Hebei, China
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
- Conditions
- Neutropenia
- Interventions
- Drug: pegfilgrastim, 60mcg/kgDrug: pegfilgrastim,30mcg/kgDrug: pegfilgrastim, 100mcg/kgDrug: filgrastim, 5mcg/kg
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 200
- Registration Number
- NCT01918241
- Locations
- 🇨🇳
Cancer Institute and Hospital, CAMS, Beijing, China
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 24
- Registration Number
- NCT01637493
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
- Conditions
- NauseaVomitingChemotherapy
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 144
- Registration Number
- NCT00503386
- Locations
- 🇨🇳
Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Hunan Provincial Tumor Hospital, Changsha, Hunan, China